<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00015977</url>
  </required_header>
  <id_info>
    <org_study_id>9845</org_study_id>
    <secondary_id>UCCRC-9845</secondary_id>
    <secondary_id>NCI-1192</secondary_id>
    <nct_id>NCT00015977</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy</brief_title>
  <official_title>Phase II Study of Immunization With PSMA Peptide-Pulsed Autologous PBMC Plus rhIL-12 in Patients With Metastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a patient's white blood cells may make the body build an immune&#xD;
      response to kill cancer cells. Interleukin-12 may kill cancer cells by stopping blood flow to&#xD;
      the tumor and by stimulating a person's white blood cells to kill cancer cells. Combining&#xD;
      vaccine therapy with interleukin-12 may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of vaccine therapy combined with&#xD;
      interleukin-12 in treating patients who have metastatic prostate cancer that has not&#xD;
      responded to hormone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether immunization with prostate-specific membrane antigen-pulsed autologous&#xD;
           peripheral blood mononuclear cells and interleukin-12 can promote specific T-cell&#xD;
           priming in patients with metastatic hormone-refractory prostate cancer.&#xD;
&#xD;
        -  Determine the clinical response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive prostate-specific membrane antigen-pulsed autologous peripheral&#xD;
      blood mononuclear cells subcutaneously (SC) on day 1 and interleukin-12 SC on days 1, 3, and&#xD;
      5. Treatment repeats every 21 days for 3-9 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 37 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease response</measure>
    <time_frame>63 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>PSMA peptide vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunization with PSMA peptide vaccine followed by injection of Interleukin-12 (IL-12) on Day 1 of a 21-day cycle. Additional injections of IL-12 given on Days 3 and 5 of each cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PSA prostate cancer vaccine</intervention_name>
    <arm_group_label>PSMA peptide vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interleukin-12</intervention_name>
    <arm_group_label>PSMA peptide vaccine</arm_group_label>
    <other_name>IL-12, rhIL-12</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic adenocarcinoma of the prostate&#xD;
&#xD;
          -  HLA-A2 positive&#xD;
&#xD;
          -  Progressive measurable systemic disease&#xD;
&#xD;
               -  PSA at least 5 ng/mL with 2 consecutive rising PSA levels at least 1 week apart&#xD;
                  and no measurable disease OR&#xD;
&#xD;
               -  Objective evidence of disease progression by a 20% increase in the sum of longest&#xD;
                  diameter of all target lesions or evidence of new lesions by CT or bone scan&#xD;
                  regardless of PSA status&#xD;
&#xD;
               -  Lesions must be at least 1 cm to be considered measurable&#xD;
&#xD;
               -  Progressive systemic disease after discontinuation of anti-androgen therapy&#xD;
&#xD;
          -  Previously treated with orchiectomy (testosterone less than 50 ng/mL) OR luteinizing&#xD;
             hormone-releasing hormone (LHRH) analogue therapy with or without anti-androgens&#xD;
&#xD;
               -  If on LHRH analogue therapy, must continue therapy during study&#xD;
&#xD;
          -  Brain metastases allowed if previously treated, clinically stable, and weaned from&#xD;
             prior corticosteroids&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 9 g/dL&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  No active gastrointestinal bleeding&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGPT normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 times ULN&#xD;
&#xD;
          -  Calcium less than 11 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No significant cardiovascular disease&#xD;
&#xD;
          -  No cardiac arrhythmia requiring therapy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  No intrinsic immunosuppression&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No serious concurrent infection&#xD;
&#xD;
          -  No psychiatric illness that would preclude study compliance&#xD;
&#xD;
          -  No clinically significant autoimmune disease&#xD;
&#xD;
          -  No uncontrolled peptic ulcer disease&#xD;
&#xD;
          -  No history of inflammatory bowel disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior flutamide&#xD;
&#xD;
          -  At least 6 weeks since prior bicalutamide or nilutamide&#xD;
&#xD;
          -  No concurrent systemic corticosteroids except physiologic replacement doses&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent immunosuppressive drugs (e.g., cyclosporine)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas F. Gajewski, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 6, 2014</last_update_submitted>
  <last_update_submitted_qc>March 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-12</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

